|
|
|
|
|
|
|
|
|
|
|
 
|
Pancreas Cancer
News and Archives |
|
|
Early Data Shows Positive
Indicators of Anti-Tumor Activity with Gimatecan, a Novel Oral
Camptothecin Derivative Preliminary data showing positive indicators of anti-tumor activity with the oral camptothecin derivative gimatecan (ST1481) were presented today at the 39th annual meeting of the American Society of Clinical Oncology. The data also show improvements in dose schedule-dependent tolerability in patients with solid tumors, confirming the development potential of gimatecan as a possible cancer treatment. ...full article |
||
|
||
|
For educational
purposes only; not to be relied upon Please read Pancreatica Disclaimer |
||
 Home | In The News | Links | Newswire | Donations FAQ | Clinical Trials Database | Research Resources | About Us |
||
|
|
||
|
www.pancreatica.org |
||